APIMEDS PHARMACEUTICALS US, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
APIMEDS PHARMACEUTICALS US, INC. (APUS) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $2.30 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-14
- APIMEDS PHARMACEUTICALS US, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $448.49K, a 296.45% increase year-over-year.
- APIMEDS PHARMACEUTICALS US, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-06-30 was -$816.06K, a 435.57% decline year-over-year.
- APIMEDS PHARMACEUTICALS US, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-03-31 was $344.01K, a 6506.72% increase year-over-year.
- APIMEDS PHARMACEUTICALS US, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2024-12-31 was $175.23K.
- APIMEDS PHARMACEUTICALS US, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $536.75K, a 904.48% increase from fiscal 2023.
- APIMEDS PHARMACEUTICALS US, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $53.44K.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.30M 10-Q · filed 2026-08-14 | |||
| 2025-09-30 | $448.49K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$367.57K derived: sum of 2 quarters · filed 2026-08-14 | -$23.56K 10-Q · filed 2025-11-12 | $151.68K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$816.06K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$472.05K 10-Q · filed 2026-08-14 | -$296.82K derived: sum of 3 quarters · filed 2026-08-14 | -$183.69K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $344.01K 10-Q · filed 2025-05-20 | $519.25K derived: sum of 2 quarters · filed 2025-05-20 | $632.37K derived: sum of 3 quarters · filed 2025-11-12 | $875.56K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-12-31 | $175.23K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $288.36K derived: sum of 2 quarters · filed 2025-11-12 | $531.54K derived: sum of 3 quarters · filed 2025-11-12 | $536.75K 10-K · filed 2025-04-15 |
| 2024-09-30 | $113.13K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $356.31K derived: sum of 2 quarters · filed 2025-11-12 | $361.52K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $243.18K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-19 | $248.39K 10-Q · filed 2025-08-19 | ||
| 2024-03-31 | $5.21K 10-Q · filed 2025-05-20 | |||
| 2023-12-31 | $53.44K 10-K · filed 2025-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |